2024 - 2032 年癌胚抗原 (CEA) 市場機會、成長動力、產業趨勢分析與預測

Carcinoembryonic Antigen (CEA) Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032

出版日期: 2024年09月30日 | 出版商:

Global Market Insights Inc. | 英文 130 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2023 年，全球癌胚抗原(CEA) 市場估值為22 億美元，預計2024 年至2032 年複合年成長率為6.3%。的。據世界衛生組織 (WHO) 稱，全球癌症負擔預計將激增，到 2040 年預計將有約 2700 萬新發病例和 1600 萬癌症相關死亡。佔所有癌症診斷的首位，在癌症相關死亡率中排名第二。癌症盛行率的增加刺激了對 CEA 檢測的需求，這對於監測治療反應、檢測復發和幫助早期診斷至關重要。根據應用，CEA 市場分為胃腸癌、乳癌、肺癌、卵巢癌、前列腺癌和甲狀腺癌。

到 2023 年，胃腸癌細分市場將佔據市場主導地位，佔據 41.4% 的佔有率，預計在預測期內將以 6.7% 的複合年成長率成長。該細分市場涵蓋各種癌症，包括結直腸癌、胰腺癌、肝癌、胃癌、食道癌、膽囊癌和肛門癌，CEA 測試在監測這些疾病方面發揮著至關重要的作用。該市場也按性別分類，到2023 年，男性細分市場將佔據54.8% 的可觀佔有率。的盛行率很高。雖然 CEA 不是前列腺癌的主要生物標記物，但它經常與其他診斷方法一起使用，以追蹤疾病進展和治療結果，使其成為男性癌症護理的寶貴工具。，到2023 年將產生8.301 億美元的收入，預計未來幾年將大幅成長。美國市場的主導地位可歸因於其先進的醫療基礎設施、胃腸道癌症的高盛行率以及持續的研究工作。此外，該國在診斷創新方面的領先地位提高了 CEA 檢測的準確性和可靠性，進一步推動了該地區市場的成長。

市場範圍
開始年份	2023年
預測年份	2024-2032
起始值	22億美元
預測值	38億美元
複合年成長率	6.3%

產業生態系統
產業影響力
- 成長動力
  - 癌症盛行率上升
  - 對微創診斷程序的需求不斷成長
  - 癌胚抗原診斷的最新技術進展
  - 人均醫療保健支出增加
- 產業陷阱與挑戰
  - 無法檢測早期癌症
  - 對癌胚抗原檢測的應用缺乏認知
成長潛力分析
監管環境
- 美國
- 歐洲
2023 年全球主要癌症發生率（按地區）
- 北美癌症發生率
- 歐洲癌症發生率
- 亞太地區癌症發生率
- 拉丁美洲癌症發生率
- 中東和非洲癌症發生率
臨床研究景觀
波特的分析
PESTEL分析

第 4 章：競爭格局

介紹
- F. Hoffmann-La Roche Ltd.
- Quest Diagnostics Incorporated
- Thermo Fisher Scientific Inc.
主要市場參與者的競爭分析
公司矩陣分析
競爭定位矩陣
戰略儀表板

第 5 章：市場估計與預測：按應用分類，2021 - 2032

主要趨勢
胃腸癌
- 大腸直腸癌
- 胰腺癌
- 肝癌
- 胃癌
- 食道癌
- 膽囊癌
- 肛門癌
乳癌
肺癌
卵巢癌
攝護腺癌
甲狀腺癌

第 6 章：市場估計與預測：按性別分類，2021 - 2032 年

主要趨勢
男性
女性

第 7 章：市場估計與預測：按最終用戶分類，2021 - 2032 年

主要趨勢
醫院
診斷實驗室
腫瘤診所
研究中心和學術機構

第 8 章：市場估計與預測：按地區，2021 - 2032

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 波蘭
- 俄羅斯
- 瑞典
- 瑞士
- 荷蘭
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 紐西蘭
- 馬來西亞
- 新加坡
- 印尼
- 菲律賓
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 哥倫比亞
- 秘魯
- 拉丁美洲其他地區
中東和非洲
- 沙烏地阿拉伯
- 南非
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 9 章：公司簡介

Abcam Limited
AdvaCare Pharma
Aviva Systems Biology Corporation
Boster Biological Technology
Creative Diagnostics
Diazyme Laboratories Inc.
F. Hoffmann-La Roche Ltd.
Medix Biochemica
Omega Diagnostics Ltd.
RayBiotech, Inc.
Thermo Fisher Scientific Inc.
Quest Diagnostics Incorporated

簡介目錄

Product Code: 427

The Global Carcinoembryonic Antigen (CEA) Market was valued at USD 2.2 billion in 2023 and is projected to grow at a 6.3% CAGR from 2024 to 2032. The market expansion is largely driven by the rising incidence of cancers such as colorectal, lung, and breast cancers worldwide. According to the World Health Organization (WHO), the global cancer burden is expected to surge, with around 27 million new cases and 16 million cancer-related deaths anticipated by 2040. Colorectal cancer is the third most common type globally, accounting for 10% of all cancer diagnoses and ranking second in cancer-related mortality. The increasing cancer prevalence has fueled the demand for CEA tests, which are essential for monitoring treatment responses, detecting recurrences, and aiding in early diagnosis. By application, the CEA market is segmented into gastrointestinal, breast, lung, ovarian, prostate, and thyroid cancers.

The gastrointestinal cancer segment dominated the market in 2023, holding a 41.4% share and is expected to grow at a 6.7% CAGR over the forecast period. This segment encompasses various cancers, including colorectal, pancreatic, liver, stomach, esophageal, gall bladder, and anal cancers, with CEA tests playing a crucial role in monitoring these conditions. The market is also categorized by gender, with the male segment capturing a substantial share of 54.8% in 2023. This segment is projected to reach a market size of USD 2.1 billion by 2032. The high prevalence of cancers such as colorectal, lung, and prostate cancers in men has led to increased adoption of CEA testing. While CEA is not the primary biomarker for prostate cancer, it is frequently used alongside other diagnostics to track disease progression and treatment outcomes, making it a valuable tool in men's cancer care.In terms of regional analysis, the U.S. led the North American CEA market, generating USD 830.1 million in revenue in 2023, with significant growth expected over the coming years. The U.S. market's dominance can be attributed to its advanced healthcare infrastructure, high prevalence of gastrointestinal cancers, and ongoing research efforts. Additionally, the country's leadership in diagnostic innovation has enhanced the accuracy and reliability of CEA assays, further driving the market's growth in the region.

Market Scope
Start Year	2023
Forecast Year	2024-2032
Start Value	$2.2 Billion
Forecast Value	$3.8 Billion
CAGR	6.3%

Chapter 1 Methodology & Scope

1.1 Market segmentation
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculations
- 1.3.2 Key trends for market estimates
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Rising in cancer prevalence
  - 3.2.1.2 Growing demand for minimally invasive diagnostic procedures
  - 3.2.1.3 Recent technological advancements in carcinoembryonic antigen diagnostics
  - 3.2.1.4 Increasing per capita healthcare expenditure
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Inability to detect early-stage cancer
  - 3.2.2.2 Lack of awareness regarding the application of carcinoembryonic antigen tests
3.3 Growth potential analysis
3.4 Regulatory landscape
- 3.4.1 U.S.
- 3.4.2 Europe
3.5 Global incidence of top cancers, by region, 2023
- 3.5.1 North America cancer incidence
- 3.5.2 Europe cancer incidence
- 3.5.3 Asia Pacific cancer incidence
- 3.5.4 Latin America cancer incidence
- 3.5.5 Middle East & Africa cancer incidence
3.6 Clinical studies landscape
3.7 Porter's analysis
3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
- 4.1.1 F. Hoffmann-La Roche Ltd.
- 4.1.2 Quest Diagnostics Incorporated
- 4.1.3 Thermo Fisher Scientific Inc.
4.2 Competitive analysis of major market players
4.3 Company matrix analysis
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Gastrointestinal cancer
- 5.2.1 Colorectal cancer
- 5.2.2 Pancreatic cancer
- 5.2.3 Liver cancer
- 5.2.4 Stomach cancer
- 5.2.5 Esophageal cancer
- 5.2.6 Gall bladder cancer
- 5.2.7 Anal cancer
5.3 Breast cancer
5.4 Lung cancer
5.5 Ovarian cancer
5.6 Prostate cancer
5.7 Thyroid cancer

Chapter 6 Market Estimates and Forecast, By Gender, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Male
6.3 Female

Chapter 7 Market Estimates and Forecast, By End-user, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Hospitals
7.3 Diagnostic laboratories
7.4 Oncology clinics
7.5 Research centers and academic institutes

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Poland
- 8.3.7 Russia
- 8.3.8 Sweden
- 8.3.9 Switzerland
- 8.3.10 Netherlands
- 8.3.11 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 New Zealand
- 8.4.7 Malaysia
- 8.4.8 Singapore
- 8.4.9 Indonesia
- 8.4.10 Philippines
- 8.4.11 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.5.4 Columbia
- 8.5.5 Peru
- 8.5.6 Rest of Latin America
8.6 Middle East and Africa
- 8.6.1 Saudi Arabia
- 8.6.2 South Africa
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa